Corteva CTVA

NYSE CTVA

$84.74 -1.16 (-1.35%)

As of: Sep 9, 2026 · 3:59 PM EDT

Key Stats

Market Cap56.80 Bn

P/E55.64

P/S3.19

Div. Yield0.02

Total Debt (Qtr)4.88 Bn

Revenue Growth (1y) (Qtr)-1.19

Add ratio to table…

About

Corteva is a leading global provider of seed and crop protection solutions focused on the agriculture industry and contributing to a healthier more secure and sustainable food supply. The company develops produces and markets a broad portfolio of agriculture products that help farmers improve productivity and profitability across approximately 110 countries. Corteva leverages its scientific heritage and innovation pipeline to deliver advanced germplasm trait technologies and…

Corteva generates revenue primarily through the sale of seed products and crop protection products to farmers worldwide. Its Seed segment sells commercial seed combined with advanced traits that boost yield and resilience to weather pests diseases and herbicides. The Crop Protection segment sells herbicides insecticides fungicides seed treatments nitrogen stabilizers and biologicals that protect crops and support soil health. In addition the company earns income from licensing its germplasm and trait technologies to third parties and from offering digital agronomy services that provide data driven insights to farmers.

The company operates through the following segments: Seed and Crop Protection.

Seed: This segment develops and supplies commercial seed that combines superior germplasm with advanced traits to deliver high yield potential for farmers around the world. It offers a wide range of brands and technologies including corn soybean cotton and canola seeds along with trait packages such as ENLIST E3 PowerCore Qrome and Optimum AcreMax. The segment also provides seed treatments digital solutions and a multi channel distribution model that includes the Pioneer agency model regional seed brands retail outlets and third party licensing.
Crop Protection: This segment supplies products that protect crop yields against weeds insects disease and other pests while supporting overall crop health through nitrogen management and seed applied technologies. It provides a diverse portfolio of herbicides insecticides fungicides nitrogen stabilizers pasture and range management products and biologicals. The segment markets its solutions under brands such as ENLIST weed control system RINSKOR DURACOR VYDATE and ZORVEC and relies on a global supply chain that sources raw materials and utilizes contract manufacturers to formulate products close to end customers.

Corteva holds a leading position in the global agriculture input industry competing with major players such as BASF Bayer FMC Syngenta and ChemChina. Its competitive advantages stem from one of the broadest and most productive new product pipelines in the sector strong germplasm and trait leadership integrated digital solutions and a extensive worldwide distribution network that enables direct engagement with farmers. The company’s sustained investment in research and development and its ability to combine seed and crop protection offerings provide a differentiated value proposition.

Corteva serves a diverse customer base that includes individual growers large agricultural enterprises farming cooperatives distributors and retailers. The company’s products are used by farmers producing a variety of row crops specialty crops and pasture lands across North America Latin America Europe Africa and Asia Pacific.

Investment Thesis

▲ Bull case

CTVA is positioned to benefit from a structural shift in global agriculture where farmers are prioritizing yield-enhancing technologies despite tight margins, as evidenced by strong price mix gains across all regions in Q1 2026, indicating that growers are actively choosing CTVA’s latest hybrids and traits like Enlist E3 soybeans to improve profitability per acre even when input costs are high. This behavior is not a temporary response to favorable weather but a sustained strategic shift toward productivity-focused input choices, which supports durable demand for CTVA’s premium seed portfolio and reduces elasticity to price fluctuations, creating a more resilient revenue base than the market currently anticipates. The company’s ability to achieve 3% price mix growth in seed during a period of farmer caution underscores the strength of its value proposition and suggests that its innovation pipeline is delivering tangible economic benefits to growers, which will continue to drive adoption and pricing power through 2026 and beyond.
The progression toward royalty positivity in the seed business represents a significant, underappreciated catalyst that will unlock substantial incremental earnings power, with CTVA already realizing a $30 million reduction in net royalty expense in Q1 2026 due to strong demand for Enlist traits under the Bayer agreement, signaling that licensing revenue is scaling faster than anticipated and could exceed the $1 billion cumulative opportunity over the next decade as management highlighted. This shift transforms the seed business from a cost center burdened by royalties to a net income generator, with the potential to contribute meaningfully to EBITDA growth as early as late 2026, particularly as the company expands its licensing model into Brazil where it aims to achieve double-digit trait penetration in soybeans—leveraging its dominant corn position to cross-sell soybean technology and create a virtuous cycle of market share gains and recurring revenue.
CTVA’s strategic investments in biologicals and next-generation biofuel feedstocks are establishing early-mover advantages in high-growth adjacencies that are not yet reflected in current valuations, with the company’s Utrisha and BlueN products already showing double-digit growth in Latin America driven by fertilizer cost pressures, and its sustainable aviation fuel partnerships with Bunge, Chevron, and BP demonstrating traction through over 90% farmer retention rates and plans to expand from 100,000 to 400,000 acres by 2027. These initiatives address structural shifts in global agriculture toward sustainability and decarbonization, positioning CTVA to capture premium pricing and long-term contracts in emerging markets like low-carbon fuels and biological nitrogen fixation, which could evolve into multi-billion dollar opportunities beyond traditional crop protection and seed segments.
The upcoming separation into two focused, pure-play entities—Vylor (seed) and New Corteva (crop protection)—is poised to unlock value through improved strategic clarity, reduced complexity, and enhanced execution, with management explicitly targeting investment-grade credit profiles for both companies and having already made a $1.5 billion discretionary pension contribution to strengthen the balance sheet of New Corteva, which will improve its standalone financial flexibility and reduce perceived risk. This deconsolidation will allow investors to value each business on its own merits, potentially revealing hidden sum-of-the-parts value as Vylor’s high-margin, royalty-positive seed model and New Corteva’s differentiated pipeline (including seven new actives and growing biologics) become more transparent, a dynamic that has historically driven re-rating in similar agricultural spin-offs.

CTVA is positioned to benefit from a structural shift in global agriculture where farmers are prioritizing yield-enhancing technologies despite tight margins, as evidenced by strong price mix gains across all regions in Q1 2026, indicating that growers are actively choosing CTVA’s latest hybrids and traits like Enlist E3 soybeans to improve profitability per acre even when input costs are high. This behavior is not a temporary response to favorable weather but a sustained strategic shift toward productivity-focused input choices, which supports durable demand for CTVA’s premium seed portfolio and reduces elasticity to price fluctuations, creating a more resilient revenue base than the market currently anticipates. The company’s ability to achieve 3% price mix growth in seed during a period of farmer caution underscores the strength of its value proposition and suggests that its innovation pipeline is delivering tangible economic benefits to growers, which will continue to drive adoption and pricing power through 2026 and beyond.
The progression toward royalty positivity in the seed business represents a significant, underappreciated catalyst that will unlock substantial incremental earnings power, with CTVA already realizing a $30 million reduction in net royalty expense in Q1 2026 due to strong demand for Enlist traits under the Bayer agreement, signaling that licensing revenue is scaling faster than anticipated and could exceed the $1 billion cumulative opportunity over the next decade as management highlighted. This shift transforms the seed business from a cost center burdened by royalties to a net income generator, with the potential to contribute meaningfully to EBITDA growth as early as late 2026, particularly as the company expands its licensing model into Brazil where it aims to achieve double-digit trait penetration in soybeans—leveraging its dominant corn position to cross-sell soybean technology and create a virtuous cycle of market share gains and recurring revenue.
CTVA’s strategic investments in biologicals and next-generation biofuel feedstocks are establishing early-mover advantages in high-growth adjacencies that are not yet reflected in current valuations, with the company’s Utrisha and BlueN products already showing double-digit growth in Latin America driven by fertilizer cost pressures, and its sustainable aviation fuel partnerships with Bunge, Chevron, and BP demonstrating traction through over 90% farmer retention rates and plans to expand from 100,000 to 400,000 acres by 2027. These initiatives address structural shifts in global agriculture toward sustainability and decarbonization, positioning CTVA to capture premium pricing and long-term contracts in emerging markets like low-carbon fuels and biological nitrogen fixation, which could evolve into multi-billion dollar opportunities beyond traditional crop protection and seed segments.
The upcoming separation into two focused, pure-play entities—Vylor (seed) and New Corteva (crop protection)—is poised to unlock value through improved strategic clarity, reduced complexity, and enhanced execution, with management explicitly targeting investment-grade credit profiles for both companies and having already made a $1.5 billion discretionary pension contribution to strengthen the balance sheet of New Corteva, which will improve its standalone financial flexibility and reduce perceived risk. This deconsolidation will allow investors to value each business on its own merits, potentially revealing hidden sum-of-the-parts value as Vylor’s high-margin, royalty-positive seed model and New Corteva’s differentiated pipeline (including seven new actives and growing biologics) become more transparent, a dynamic that has historically driven re-rating in similar agricultural spin-offs.

▼ Bear case

CTVA’s exposure to volatile energy markets presents a material and under-discussed risk to its cost structure and farmer demand, particularly through the indirect impact of higher oil prices on nitrogen fertilizer costs, which the company acknowledged could influence planting decisions in Brazil’s safrinha season if sustained, potentially undermining its flat acreage assumption and reducing demand for seed and crop protection products in a key growth market; while CTVA downplayed near-term U.S. impacts due to pre-purchased inputs, the global nature of fertilizer markets means that prolonged energy inflation could erode farmer margins globally, leading to more cautious input spending and a shift toward lower-cost alternatives that disproportionately affect CTVA’s premium-priced offerings.
The company’s reliance on pricing power in seed to offset volume pressures in crop protection may not be sustainable, as CTVA admitted crop protection pricing remains under pressure with low single-digit declines expected year-over-year, and while it expects mid single-digit volume gains to more than offset this, the assumption hinges on continued strength in biologicals and new products like Spinosyns—categories that are inherently more volatile and subject to pest pressure fluctuations, which could reverse quickly if environmental conditions change, leaving the business vulnerable to a scenario where both volume and pricing in crop protection deteriorate simultaneously during periods of economic stress.
Although CTVA highlighted progress in reducing net dis-synergies from the separation to $50 million in guidance, the process still involves significant execution risk, including the integration of newly appointed leadership teams (such as Luke Kism as CEO of New Corteva) and the potential for cultural misalignment during the separation, which could distract from core operations and lead to inefficiencies that erode the anticipated cost savings, particularly given the complexity of splitting over 22,000 employees and the historical challenges of executing large-scale corporate separations in agriculture where shared R&D and supply chain functions are difficult to disentangle without unintended consequences.
The anticipated growth in biologicals and next-gen traits may be overstated, as CTVA’s own guidance assumes only modest overall crop protection market growth (low single-digit volume gains) with its outperformance relying on specific categories like Spinosyns and biologicals, yet the company provided no clear timeline for when its biofuel feedstock programs (e.g., sustainable aviation fuel mustard and winter canola) will meaningfully contribute to revenue, noting that commercial-scale planting in Latin America will not begin until 2027, which creates a prolonged investment period with uncertain returns and raises questions about whether these initiatives will achieve scale quickly enough to justify current optimism, especially given the capital intensity and long development cycles typical of agricultural biotech innovations.

CTVA’s exposure to volatile energy markets presents a material and under-discussed risk to its cost structure and farmer demand, particularly through the indirect impact of higher oil prices on nitrogen fertilizer costs, which the company acknowledged could influence planting decisions in Brazil’s safrinha season if sustained, potentially undermining its flat acreage assumption and reducing demand for seed and crop protection products in a key growth market; while CTVA downplayed near-term U.S. impacts due to pre-purchased inputs, the global nature of fertilizer markets means that prolonged energy inflation could erode farmer margins globally, leading to more cautious input spending and a shift toward lower-cost alternatives that disproportionately affect CTVA’s premium-priced offerings.
The company’s reliance on pricing power in seed to offset volume pressures in crop protection may not be sustainable, as CTVA admitted crop protection pricing remains under pressure with low single-digit declines expected year-over-year, and while it expects mid single-digit volume gains to more than offset this, the assumption hinges on continued strength in biologicals and new products like Spinosyns—categories that are inherently more volatile and subject to pest pressure fluctuations, which could reverse quickly if environmental conditions change, leaving the business vulnerable to a scenario where both volume and pricing in crop protection deteriorate simultaneously during periods of economic stress.
Although CTVA highlighted progress in reducing net dis-synergies from the separation to $50 million in guidance, the process still involves significant execution risk, including the integration of newly appointed leadership teams (such as Luke Kism as CEO of New Corteva) and the potential for cultural misalignment during the separation, which could distract from core operations and lead to inefficiencies that erode the anticipated cost savings, particularly given the complexity of splitting over 22,000 employees and the historical challenges of executing large-scale corporate separations in agriculture where shared R&D and supply chain functions are difficult to disentangle without unintended consequences.
The anticipated growth in biologicals and next-gen traits may be overstated, as CTVA’s own guidance assumes only modest overall crop protection market growth (low single-digit volume gains) with its outperformance relying on specific categories like Spinosyns and biologicals, yet the company provided no clear timeline for when its biofuel feedstock programs (e.g., sustainable aviation fuel mustard and winter canola) will meaningfully contribute to revenue, noting that commercial-scale planting in Latin America will not begin until 2027, which creates a prolonged investment period with uncertain returns and raises questions about whether these initiatives will achieve scale quickly enough to justify current optimism, especially given the capital intensity and long development cycles typical of agricultural biotech innovations.

Geographical Breakdown of Revenue (2025)

Peer group

Peer Comparison

Companies in the Crop Protection and Seeds

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	CTVA	Corteva, Inc.	primary	56.80 Bn	55.64	3.19	4.88 Bn
2	FMC	Fmc Corp	primary	1.54 Bn	-0.56	0.48	4.29 Bn
3	CBUS	Cibus, Inc.	primary	0.12 Bn	-1.16	33.91	0.00 Bn
4	AVD	American Vanguard Corp	primary	0.06 Bn	-1.54	0.13	0.27 Bn
5	BIOX	Bioceres Crop Solutions Corp.	primary	0.03 Bn	-0.39	0.10	0.17 Bn
6	GNVR	Genvor Inc	primary	0.02 Bn	-7.21	-	0.00 Bn
7	SEED	Origin Agritech LTD	primary	0.01 Bn	-	-	0.01 Bn
8	SNES	SenesTech, Inc.	primary	0.00 Bn	-0.67	1.97	0.00 Bn

Corteva CTVA

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password